Navigate the Curis CRIS Stock Research Pages
Introduction - general company overview, financials, pipeline snapshot, upcoming catalysts
ERIVEDGE (vismodegib) - FDA-approved Hedgehog inhibitor partnered with Roche/Genentech for cancer
CUDC-101 - Phase 1 multi-targeted cancer drug candidate
Debio0932 - Phase 1/2 HSP90 inhibitor partnered with Debiopharm for oncology
ERIVEDGE (vismodegib) - FDA-approved Hedgehog inhibitor partnered with Roche/Genentech for cancer
CUDC-101 - Phase 1 multi-targeted cancer drug candidate
Debio0932 - Phase 1/2 HSP90 inhibitor partnered with Debiopharm for oncology
Curis $CRISwww.curis.com
"Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs." CRIS - archive of related blog posts and articlesBlue font indicates premium content for Chimera Research Group subscribers only. 3/2012 Cowen Healthcare conference - click for my notes. 4/2012 Roth Capital Growth conference - click for my notes. 4/2012 Comments from Roche 1q-2012 earnings re ERIVEDGE (vismodegib) sales - link. 4/2012 Needham Healthcare conference - click for my notes. 5/2012 ASCO abstracts - click for part 1 - part 2. 8/2012 Notes from partner Roche 2q-2012 CC - blog. |
|
See embedded set of slides describing the key challenge of resistance to targeted cancer therapies and the approach CRIS takes to address this limitation of current treatments. Source: April 2012 investor presentation slide deck.
|